- Home
- VXRT vs FHTX Comparison
VXRT vs FHTX Comparison
Compare VXRT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VXRT
- FHTX
- Stock Information
- Founded
- VXRT N/A
- FHTX 2015
- Country
- VXRT United States
- FHTX United States
- Employees
- VXRT N/A
- FHTX N/A
- Industry
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- VXRT Health Care
- FHTX Health Care
- Exchange
- VXRT Nasdaq
- FHTX Nasdaq
- Market Cap
- VXRT 200.3M
- FHTX 237.4M
- IPO Year
- VXRT N/A
- FHTX 2020
- Fundamental
- Price
- VXRT $0.76
- FHTX $4.41
- Analyst Decision
- VXRT Strong Buy
- FHTX Strong Buy
- Analyst Count
- VXRT 2
- FHTX 5
- Target Price
- VXRT $3.00
- FHTX $13.80
- AVG Volume (30 Days)
- VXRT 2.6M
- FHTX 170.9K
- Earning Date
- VXRT 03-13-2025
- FHTX 03-06-2025
- Dividend Yield
- VXRT N/A
- FHTX N/A
- EPS Growth
- VXRT N/A
- FHTX N/A
- EPS
- VXRT N/A
- FHTX N/A
- Revenue
- VXRT $16,760,000.00
- FHTX $25,515,000.00
- Revenue This Year
- VXRT $128.77
- FHTX N/A
- Revenue Next Year
- VXRT N/A
- FHTX $7.37
- P/E Ratio
- VXRT N/A
- FHTX N/A
- Revenue Growth
- VXRT 303.27
- FHTX N/A
- 52 Week Low
- VXRT $0.52
- FHTX $2.70
- 52 Week High
- VXRT $1.54
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- VXRT 55.26
- FHTX 34.76
- Support Level
- VXRT $0.70
- FHTX $4.13
- Resistance Level
- VXRT $0.83
- FHTX $4.47
- Average True Range (ATR)
- VXRT 0.09
- FHTX 0.35
- MACD
- VXRT -0.00
- FHTX 0.07
- Stochastic Oscillator
- VXRT 36.62
- FHTX 30.77
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.